Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 3
1987 2
1988 2
1989 4
1990 1
1991 1
1992 3
1993 4
1994 4
1995 5
1996 5
1997 6
1998 8
1999 9
2000 11
2001 8
2002 6
2003 6
2004 3
2005 2
2006 5
2007 2
2008 9
2009 11
2010 8
2011 20
2012 17
2013 12
2014 15
2015 21
2016 13
2017 13
2018 16
2019 13
2020 18
2021 8
Text availability
Article attribute
Article type
Publication date

Search Results

266 results
Results by year
Filters applied: . Clear all
Page 1
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Villarino ME, et al. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. JAMA Pediatr. 2015. PMID: 25580725 Free PMC article. Clinical Trial.
Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.
Ruhwald M, Aggerbeck H, Gallardo RV, Hoff ST, Villate JI, Borregaard B, Martinez JA, Kromann I, Penas A, Anibarro LL, de Souza-Galvão ML, Sánchez F, Rodrigo-Pendás JÁ, Noguera-Julian A, Martínez-Lacasa X, Tuñez MV, Fernández VL, Millet JP, Moreno A, Cobos N, Miró JM, Roldan L, Orcau A, Andersen P, Caylá JA; TESEC Working Group. Ruhwald M, et al. Among authors: cayla ja. Lancet Respir Med. 2017 Apr;5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2. Epub 2017 Feb 1. Lancet Respir Med. 2017. PMID: 28159608 Clinical Trial.
Update of SEPAR guideline «Diagnosis and Treatment of Drug-Resistant Tuberculosis».
Caminero JA, García-García JM, Caylà JA, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Caminero JA, et al. Among authors: cayla ja. Arch Bronconeumol (Engl Ed). 2020 Aug;56(8):514-521. doi: 10.1016/j.arbres.2020.03.021. Epub 2020 May 20. Arch Bronconeumol (Engl Ed). 2020. PMID: 32446667 English, Spanish.
[Tuberculosis and solidarity].
Caylà JA, Caminero JA, Ancochea J. Caylà JA, et al. Arch Bronconeumol. 2008 Dec;44(12):657-9. Arch Bronconeumol. 2008. PMID: 19091233 Spanish. No abstract available.
Tuberculosis recurrences and predictive factors in a vulnerable population in Catalonia.
Brugueras S, Molina VI, Casas X, González YD, Forcada N, Romero D, Rodés A, Altet MN, Maldonado J, Martin-Sánchez M, Caylà JA, Orcau À, Rius C, Millet JP. Brugueras S, et al. Among authors: cayla ja. PLoS One. 2020 Jan 15;15(1):e0227291. doi: 10.1371/journal.pone.0227291. eCollection 2020. PLoS One. 2020. PMID: 31940383 Free PMC article.
266 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page